220 related articles for article (PubMed ID: 21557933)
1. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.
Bourgault S; Choi S; Buxbaum JN; Kelly JW; Price JL; Reixach N
Biochem Biophys Res Commun; 2011 Jul; 410(4):707-13. PubMed ID: 21557933
[TBL] [Abstract][Full Text] [Related]
2. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
3. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
Manral P; Reixach N
Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
[TBL] [Abstract][Full Text] [Related]
4. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
5. Cell based screening of inhibitors of transthyretin aggregation.
Reixach N; Adamski-Werner SL; Kelly JW; Koziol J; Buxbaum JN
Biochem Biophys Res Commun; 2006 Sep; 348(3):889-97. PubMed ID: 16904635
[TBL] [Abstract][Full Text] [Related]
6. Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.
Smith TP; Windsor IW; Forest KT; Raines RT
J Med Chem; 2017 Sep; 60(18):7820-7834. PubMed ID: 28920684
[TBL] [Abstract][Full Text] [Related]
7. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.
Reixach N; Deechongkit S; Jiang X; Kelly JW; Buxbaum JN
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):2817-22. PubMed ID: 14981241
[TBL] [Abstract][Full Text] [Related]
8. Rational design of potent human transthyretin amyloid disease inhibitors.
Klabunde T; Petrassi HM; Oza VB; Raman P; Kelly JW; Sacchettini JC
Nat Struct Biol; 2000 Apr; 7(4):312-21. PubMed ID: 10742177
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
Yokoyama T; Mizuguchi M
J Med Chem; 2020 Dec; 63(23):14228-14242. PubMed ID: 32914975
[TBL] [Abstract][Full Text] [Related]
10. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
11. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
Arsequell G; Planas A
Curr Med Chem; 2012; 19(15):2343-55. PubMed ID: 22471983
[TBL] [Abstract][Full Text] [Related]
12. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis.
Jono H; Anno T; Motoyama K; Misumi Y; Tasaki M; Oshima T; Mori Y; Mizuguchi M; Ueda M; Shono M; Obayashi K; Arima H; Ando Y
Biochem J; 2011 Jul; 437(1):35-42. PubMed ID: 21668413
[TBL] [Abstract][Full Text] [Related]
13. Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity.
Frangolho A; Correia BE; Vaz DC; Almeida ZL; Brito RMM
Molecules; 2020 Dec; 25(23):. PubMed ID: 33287192
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites.
Florio P; Folli C; Cianci M; Del Rio D; Zanotti G; Berni R
J Biol Chem; 2015 Dec; 290(50):29769-80. PubMed ID: 26468275
[TBL] [Abstract][Full Text] [Related]
15. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
Green NS; Foss TR; Kelly JW
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
[TBL] [Abstract][Full Text] [Related]
16. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
Wiseman RL; Green NS; Kelly JW
Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes.
Sartiani L; Bucciantini M; Spinelli V; Leri M; Natalello A; Nosi D; Maria Doglia S; Relini A; Penco A; Giorgetti S; Gerace E; Mannaioni G; Bellotti V; Rigacci S; Cerbai E; Stefani M
Biophys J; 2016 Nov; 111(9):2024-2038. PubMed ID: 27806283
[TBL] [Abstract][Full Text] [Related]
18. Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide--relevance in Alzheimer's disease.
Ribeiro CA; Saraiva MJ; Cardoso I
PLoS One; 2012; 7(9):e45368. PubMed ID: 23028965
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
Sekijima Y; Kelly JW; Ikeda S
Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
[TBL] [Abstract][Full Text] [Related]
20. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors.
Morais-de-Sá E; Pereira PJ; Saraiva MJ; Damas AM
J Biol Chem; 2004 Dec; 279(51):53483-90. PubMed ID: 15469931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
